PCT Exam 4: Trials only

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/16

encourage image

There's no tags or description

Looks like no tags are added yet.

17 Terms

1
New cards

Antithrombin trialists' collaboration 2002

75-150 mg/day of ASA helps

with CV event prevention in PAD

2
New cards

What is the point of these trails in regard to ASA?

CLIPS trial 2007

POPADAD trial 2008

JAMA Meta-analysis 2009

JAMA Low ABI population trial 2010

That aspirin helped symtopmatic PAD patients more than asymtomatic PAD patinets.

3
New cards

CLIPS trial 2007

general PAD population (3/4 symptomatic): Significant reduction in major vascular events with low-dose ASA

4
New cards

POPADAD trial 2008

asymptomatic PAD pts: No significant reduction in composite of CV events, CV death,

or CLI-related amputation with low-dose ASA

5
New cards

JAMA Meta-analysis 2009

2/3 symptomatic PAD pts: statistically significant reduction in non-fatal CVA, but no

significant difference in other CV events.

6
New cards

JAMA Low ABI population trial 2010

All asymptomatic PAD pts: No significant reduction in fatal or non-fatal CV events or

mortality.

7
New cards

CAPRIE trial 1996

Clopidogrel vs Aspirin:

Clopidogrel may reduce CV event risk more than aspirin

8
New cards

CHARISMA trial

PAD w/ no recent vascularization pts:

Aspirin vs. Clopidogrel + Aspirin:

Dual therapy little more benefit over ASA alone & helps in regards to MI & hospitalization for ischemia

BUT associated with

increased bleeding

9
New cards

CASPAR Trial

ASA + Clopidogrel following

surgical revascularization vs ASA alone:

ASA + clopidogrel combo significantly reduces composite

of MALE or death in patients with prosthetic below-knee bypass

grafting compared to ASA alone

10
New cards

Observational Study of DAPT following

endovascular revascularization vs ASA alone

Following endovascular revascularization, DAPT was

associated with small survival benefits that were sustained through

five-years of follow-up.

11
New cards

EUCLID Trial

Ticagrelor is not superior to clopidogrel for

CV event reduction in patients with symptomatic PAD

12
New cards

TRACER Study

(Vorapaxer stopped)

TRIAL STOPPED ~6

MONTHS EARLY DUE TO

PRESPECIFIED #

ENDPOINTS BEING

REACHED & ↑ ICH RISK

13
New cards

TRA2P-TIMI 50 Study

VORAPAXAR STOPPED

IN ALL PATIENTS WITH

PRIOR CVA AFTER ~2

YEARS OF FOLLOW-UP

DUE TO TRACER STUDY

ICH RISK

14
New cards

What is a summary for Vorapxer

pts with PAD: vorapaxar may ↓MALE BUT does not ↓MACE & ↑bleeding (signficant)

15
New cards

COMPASS Trial

Symptomatic PAD pts: Rivaroxaban 2.5 mg BID + low-dose ASA = ↓ MACE & MALE and ↓ bleed risk, but was associated w/ ↑major bleeding.

16
New cards

VOYAGER PAD Trial

PAD patients w/ revascularization: Rivaroxaban 2.5 mg BID + low-dose ASA ↓ MACE & MALE in , but may be associated with ↑ major bleeding.

17
New cards

STRIDE Trial

symptomatic PAD + T2DM pts: Semaglutide improved walking distance in patients